Orphazyme As Stock Fundamentals
| ORPHA Stock | DKK 915.00 9.90 1.07% |
Orphazyme AS fundamentals help investors to digest information that contributes to Orphazyme's financial success or failures. It also enables traders to predict the movement of Orphazyme Stock. The fundamental analysis module provides a way to measure Orphazyme's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Orphazyme stock.
Orphazyme |
Orphazyme AS Company Return On Equity Analysis
Orphazyme's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Orphazyme Return On Equity | -4.87 |
Most of Orphazyme's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orphazyme AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Orphazyme AS has a Return On Equity of -4.8658. This is 79.7% lower than that of the Biotechnology sector and 86.65% lower than that of the Health Care industry. The return on equity for all Denmark stocks is notably higher than that of the company.
Orphazyme AS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Orphazyme's current stock value. Our valuation model uses many indicators to compare Orphazyme value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Orphazyme competition to find correlations between indicators driving Orphazyme's intrinsic value. More Info.Orphazyme AS is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Orphazyme by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Orphazyme's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Orphazyme Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orphazyme's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Orphazyme could also be used in its relative valuation, which is a method of valuing Orphazyme by comparing valuation metrics of similar companies.Orphazyme is currently under evaluation in return on equity category among its peers.
Orphazyme Fundamentals
| Return On Equity | -4.87 | |||
| Return On Asset | -1.33 | |||
| Profit Margin | (2.76) % | |||
| Operating Margin | (15.38) % | |||
| Current Valuation | (12.81 M) | |||
| Shares Outstanding | 35.31 M | |||
| Shares Owned By Insiders | 1.36 % | |||
| Shares Owned By Institutions | 8.13 % | |||
| Price To Book | 0.47 X | |||
| Price To Sales | 1.05 X | |||
| Revenue | 36.19 M | |||
| Gross Profit | 36.19 M | |||
| EBITDA | (603.91 M) | |||
| Net Income | (626.54 M) | |||
| Cash And Equivalents | 726.93 M | |||
| Cash Per Share | 20.80 X | |||
| Total Debt | 2.48 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 4.70 X | |||
| Book Value Per Share | 2.21 X | |||
| Cash Flow From Operations | (602.57 M) | |||
| Earnings Per Share | (17.94) X | |||
| Target Price | 108.0 | |||
| Beta | 0.82 | |||
| Market Capitalization | 30.82 M | |||
| Total Asset | 173.23 M | |||
| Z Score | -2.7 | |||
| Net Asset | 173.23 M |
About Orphazyme Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Orphazyme AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orphazyme using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orphazyme AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme is traded on Copenhagen Stock Exchange in Denmark.
Pair Trading with Orphazyme
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Orphazyme position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orphazyme will appreciate offsetting losses from the drop in the long position's value.Moving together with Orphazyme Stock
Moving against Orphazyme Stock
The ability to find closely correlated positions to Orphazyme could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Orphazyme when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Orphazyme - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Orphazyme AS to buy it.
The correlation of Orphazyme is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Orphazyme moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Orphazyme AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Orphazyme can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Orphazyme Stock
Orphazyme financial ratios help investors to determine whether Orphazyme Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Orphazyme with respect to the benefits of owning Orphazyme security.